CAIN457I2401: A study of secukinumab to evaluate maintenance of response in participants with non- radiographic axial spondyloarthritis who achieved remission

Title

Code

CAIN457I2401

Type

Sperimentale con farmaco

Start Year

2025

Status

In Corso

Principal Investigator

051-6366386

francesco.ursini@ior.it

Prof. Ursini Francesco

Head

Medicine and Rheumatology

Operational unit that carry out the study

departmental simple unit

Medicina e reumatologia

Head

Prof. Ursini Francesco

Go to the details >>

Description

Studio promosso da NOVARTIS PHARMA AG - presso l’Unità Operativa SSD Medicina e Reumatologia dell’Istituto Ortopedico Rizzoli.

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. CAIN457I2401

Monday 23 June 2025, 14:38

PG0006728_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

CAIN457I2401: A study of secukinumab to evaluate maintenance of response in participants with non- radiographic axial spondyloarthritis who achieved remission

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

CAIN457I2401: A study of secukinumab to evaluate maintenance of response in participants with non- radiographic axial spondyloarthritis who achieved remission

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in